The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
Members of Japan’s vaccine and drug safety panels on April 23 called for the need to send a message to elderly people with preexisting medical conditions that they should not push themselves to receive COVID-19 vaccine shots if they are…
To read the full story
Related Article
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
- No Major Concerns over Safety of Moderna, Pfizer COVID-19 Vaccines: MHLW
June 11, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
- Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
- 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
- Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
- Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…